A 74-year-old woman comes to her family physician for a routine health maintenance visit. She has no complaints. She has hypertension and type 2 diabetes mellitus treated with losartan and metformin. She has never smoked and drinks one glass of wine weekly. Her pulse is 88/min and irregularly irregular, and blood pressure is 134/80 mm Hg. Cardiac examination shows an irregular rhythm without murmurs. ECG shows an irregularly irregular rhythm with no discernible P waves, ventricular rate 84/min, and no ST-segment changes. Echocardiography shows mild left atrial enlargement, structurally normal valves, and a left ventricular ejection fraction of 60%. Laboratory studies show creatinine 0.9 mg/dL, hemoglobin 13.1 g/dL, and platelet count 240,000/mm3. She has no history of stroke, bleeding, or falls. Which of the following is the most appropriate long-term therapy to reduce her risk of stroke?
- Aspirin 81 mg daily
- Aspirin plus clopidogrel
- Apixaban
- Warfarin with a target INR of 2.5 to 3.5
- Rate control alone without antithrombotic therapy
Show the answer and explanation
Correct answer: C. Apixaban
This woman has nonvalvular atrial fibrillation. Her CHA2DS2-VASc score is 4 (female sex, age 65-74, hypertension, diabetes), which confers a substantial annual stroke risk and warrants oral anticoagulation. Direct oral anticoagulants such as apixaban are preferred over warfarin for nonvalvular atrial fibrillation because of equal or better efficacy with less intracranial bleeding. Antiplatelet therapy is inferior to anticoagulation and is no longer recommended for stroke prevention in atrial fibrillation.
Why each option is right or wrong
- Aspirin 81 mg dailyAspirin alone provides minimal stroke protection in atrial fibrillation and is not recommended when the CHA2DS2-VASc score is ≥2.
- Aspirin plus clopidogrelDual antiplatelet therapy is inferior to anticoagulation for stroke prevention and carries similar bleeding risk.
- ApixabanCorrect: a DOAC is first-line anticoagulation for nonvalvular atrial fibrillation with a CHA2DS2-VASc score ≥2 in women.
- Warfarin with a target INR of 2.5 to 3.5Warfarin is an acceptable alternative, but the target INR for nonvalvular atrial fibrillation is 2.0 to 3.0, not 2.5 to 3.5.
- Rate control alone without antithrombotic therapyHer rate is already controlled; withholding anticoagulation leaves a high stroke risk untreated.
Nonvalvular atrial fibrillation with CHA2DS2-VASc ≥2 (women) or ≥1 (men): anticoagulate, preferably with a DOAC; aspirin is not a substitute.
References
- Atrial fibrillation: an update on management (Aust Prescr 2019 (PMC6954870))